Vaccine Targets Equipment
-
Manufactured by DSS Takara Bio India Pvt Ltdbased in INDIA
SARS-CoV-2 research is happening at breakneck speed, and scientists are trying to identify epitopes that could trigger an immune response to the virus, an important step in the development of novel vaccines. Takara Bio offers an array of innovative technologies to support this endeavor. The development of a vaccine involves an ...
-
Manufactured by EnGen Bio LLCbased in USA
represents a vaccine target. We have determined that it is critical to engineer the immunogen to allow the immune system to focus its response on the surface-exposed, highly conserved, M1 epitope. Once the immune system has done this, it will recall that response when re-challenged by any Type A influenza. ...
-
Manufactured by Frontier Biotechnologies Inc.based in CHINA
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically validated target and FB6001 is a potential first-in-class immunotherapy for hypercholesteremia. ...
-
Manufactured by Auro Vaccines LLCbased in USA
Auro Vaccines has also developed a GeneVax prime/VesiculoVax boost therapeutic vaccine that targets all eight HBV genotypes for use as an adjunct to drug ...
-
Manufactured by Auro Vaccines LLCbased in USA
Auro Vaccines is developing a GeneVav prime/VesiculoVax™ boost therapeutic vaccine that targets all HCV genotypes for use as an adjunct to drug ...
-
Manufactured by Vitruvian BioMedical, Inc.based in USA
VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine for the Prevention of Alzheimer's Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global License for YM7555 which is a Therapeutic Vaccine technology for the prevention of ...
-
Manufactured by OSE Immunotherapeuticsbased in FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as ...
-
Manufactured by Virometix AGbased in SWITZERLAND
Virometix is focusing on the development of vaccine candidates with broad protection against a diverse number of coronaviruses. Our epitope-focused SVLP-based vaccine aims to target specific regions of the Receptor Binding Domain (RBD) of the Spike protein. Proof-of-concept studies are currently ongoing using SARS-CoV-2, where five ...
-
based in BELGIUM
CuraVac is a clinical-stage biotechnology company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines (or Active Targeted Immunotherapies) for autoimmune ...
-
Manufactured by IMV Inc.based in CANADA
DPX-RSV or DPX-RSV(A) is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The DPX platform is formulated with the SHe peptide of group A RSV. The small hydrophobic glycoprotein (SH) of RSV is a type II transmembrane protein that forms pentameric transmembrane pores in infected cells. It functions as a ...
-
based in UNITED KINGDOM
We are focused on the development of the next-generation of vaccination products targeting serious diseases, using our proprietary ImplaVax® solid dose formulation and needle-free delivery ...
-
Manufactured by Elicio Therapeuticsbased in USA
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.4 Mutations in the p53 protein lead to uncontrolled tumor progression and ...
-
based in USA
. There are several types of adjuvants with different modes of action. Adjuvants form a depot of antigen at the site of inoculation with slow release of antigens. Adjuvants can improve the performance of vaccines by targeting the antigen to antigen-presenting cells, eliciting specific cytokines that direct Th1 or Th2 immune responses. Most of the adjuvants ...
-
Manufactured by Elicio Therapeuticsbased in USA
ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.1 BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of ...
-
Manufactured by Calder Biosciences, Inc.based in USA
Targeted approach, focused responses. Substantially reduced risk vis-à-vis other modalities. Successful recombinant subunit vaccines elicit the highest. Ab responses; Shingrix vs. Zostavax, Gardasil, HBsAg (Recombivax, Engerix, Heplisav), HAV (Vaqta, ...
-
Manufactured by Kemin Industries Incbased in USA
Live attenuated Newcastle disease virus vaccine ...
-
Manufactured by Kemin Industries Incbased in USA
Live attenuated Infectious Bronchitis disease virus vaccine (CLASSIC ...
-
Manufactured by Calder Biosciences, Inc.based in USA
Calder’ protein engineering technology is based on targeted di-tyrosine (DT) crosslinking, which allows proteins to be locked in desired shapes. We apply this methodology to engineer novel vaccines that are locked in the shapes that elicit the most potently protective antibody ...
-
based in USA
be that previous vaccine models used inadequate vaccine designs and/or target ...
-
by BacVax, Inc.based in USA
Current commercial bacterial vaccines use toxin neutralization, capsule targeting, or multiple proteins. While these methods may work in some circumstances, many bacteria do not have toxin or capsule targets, and using several proteins in a vaccine is expensive and opens the opportunity for genetic escape by the bacteria. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you